All canine diagnoses

Your dog was diagnosed with Synovial Cell Sarcoma. Uncommon tumour arising from periarticular tissues. Locally aggressive with metastatic potential, particularly in high-grade tumours. Often presents as progressive lameness with periarticular swelling. Compare 3 treatment options for dogs including Amputation (Above Affected Joint), Palliative Management (Non-Amputation Candidates), Palliative Management (Non-Amputation Candidates) — with survival times, costs, and what to expect during treatment.

🐕

Synovial Cell Sarcoma

BreedsMedium to large breed dogs
canine

Mesenchymal

About This Cancer

Synovial cell sarcoma is an uncommon cancer arising from the soft tissues around joints — including the joint capsule, tendons, and bursae. Despite its name, modern understanding suggests it does not arise directly from synovial cells but rather from undifferentiated mesenchymal cells near joints. The tumour most frequently affects the stifle (knee), elbow, or shoulder, presenting as progressive lameness with firm swelling around the affected joint. It is locally aggressive, destroying surrounding bone and soft tissue, and high-grade tumours have meaningful metastatic potential, particularly to the lungs. Treatment usually requires amputation of the affected limb above the involved joint, as the intimate relationship with the joint makes limb-sparing surgery very difficult. Medium to large breed dogs are typically affected.

Prognostic Factors(2)
Surgical approachAmputation MST 850 days vs marginal resection MST 455 days — significant difference.(Craig et al., 2002 (35 dogs))
Histological gradeGrade I: MST 365–1,460 days. Grade II: 156–1,095 days. Grade III: 183 days.(Craig et al., 2002)
Minimum Workup(5 steps)
1Radiographs of affected joint
2Biopsy with histopathological grading
3Three-view thoracic radiographs
4Complete blood count and biochemistry
5CT/MRI for surgical planning

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Amputation (Above Affected Joint)
~28 mo
Palliative Management (Non-Amputation Candidates)
See notes
Palliative Management (Non-Amputation Candidates)
See notes
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.